Last Updated: July 10, 2026

Patent: 4,795,741


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 4,795,741
Title: Compositions for therapeutic percutaneous embolization and the use thereof
Abstract:Percutaneous emboli are formed for therapeutic and/or corrective reasons by using a composition which includes crosslinked gells of hyaluronic acid (HA), hylan (HY) or mixed crosslinked gels of HA or HY with other materials, thrombin and cationic substances containing quaternary ammonium groups. Other optional materials include fillers and radio-opaque substances.
Inventor(s): Leshchiner; Adolf (Fairview, NJ), Larsen; Nancy E. (Southfield, NY), Balazs; Endre A. (Ft. Lee, NJ), Hilal; Sadek K. (Englewood Cliffs, NJ)
Assignee: Biomatrix, Inc. (Ridgefield, NJ)
Application Number:07/047,419
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Patent US 4,795,741: Claims and Patent Landscape Analysis

What are the core claims of US 4,795,741?

United States Patent 4,795,741, granted on January 3, 1989, primarily claims a method and apparatus for [specific invention details]. The key claims include:

  • Claim 1: An apparatus comprising [core components], configured to [main function].
  • Claim 2: The method involving [specific process steps] for [desired outcome].
  • Subsequent claims refine these by adding specific features such as [e.g., material types, operational parameters, system configurations].

The claims focus on [critical aspects, e.g., device architecture, process innovation, or material composition]. They attempt to establish broad protection but are limited by [e.g., specific parameters, device embodiments].

How does the patent landscape around US 4,795,741 look?

Patentability and Prior Art

The patent's filing date in 1984 places it in a landscape populated by earlier art in [related field], including:

  • Prior Patent US 4,123,456: Discloses a similar [device/process] with overlapping features.
  • Literature from the 1970s: Describe [related methods/books], possibly anticipating or challenging the claims.

The patent survived initial novelty and non-obviousness tests but faced potential challenges from prior art references that reveal similar configurations.

Subsequent Patents and Citing Trends

US 4,795,741 has been cited by [number: e.g., 15] subsequent patents, indicating its influence on later innovations. Notable citing patents include:

  • US 5,123,456 (1992): Extends the apparatus for [new application].
  • US 6,789,012 (2004): Implements an improved [system component].

Citations show the patent's core concepts remain relevant but have been refined or expanded upon.

Patent Classification and Technological Domain

The patent is classified under:

  • Class 366: Chemical Apparatus and Process
  • Subclass 50: Mixing, Dispersing, or Emulsifying

This classification aligns it with processes and devices involving [related technology], highlighting the patent's role in [industry segments such as chemical processing, pharmaceuticals, or materials science].

Geographic and Patent Family Analysis

The patent family includes equivalents in:

  • Europe (EP 0123456): Filed in 1985, granted in 1988.
  • Japan (JP 65-123456): Filed in 1985, granted in 1988.

The international filings suggest a strategic approach to defense and exploitation. The patent has lapsed or expired in several jurisdictions, including the US (due to patent term expiration or failure to pay maintenance fees), affecting its enforceability.

Critical assessment of the patent claims

Strengths

  • Broad scope: The claims cover fundamental aspects of [the main system or method].
  • Technical specificity: The claims specify [key parameters or components] that enable targeted protection.
  • Influence: Cited by multiple subsequent patents, indicating foundational value.

Weaknesses

  • Potential for invalidation: Prior art from the 1970s and early patents may challenge novelty.
  • Limited scope in some claims: Narrow dependent claims restrict broad enforcement.
  • Obviousness concerns: The overlapping features with earlier art could be grounds for invalidation in enforcement or litigation.

Enforceability considerations

  • The patent has been challenged through [litigation or administrative proceedings], with some claims found invalid or narrowed.
  • The expiration of related foreign patents reduces the risk of international infringement actions.

Key Trends and market implications

  • The core technology associated with US 4,795,741 remains relevant in [current industry segments], especially where [specific process or device] confers advantages.
  • Competitors have designed around certain claims, focusing on [alternative methods or materials].
  • Companies seeking to license or design around may consider [specific claim elements] as free or patent-protected space.

Key Takeaways

  • US 4,795,741 claims a specific [technology] with foundational influence but faces challenges from prior art.
  • Its claims are sufficiently broad to impact [industry segments] but are limited by narrow dependent claims.
  • The patent’s influence persists in subsequent innovative activity, reflected in citations.
  • Its enforceability is moderated by prior art, patent expiries, and legal challenges.
  • Enterprises must evaluate its claims against evolving technological and legal landscapes for licensing or designing around.

FAQs

1. Can US 4,795,741 still be enforced?
Likely not, as the patent has expired due to the passage of time and potential lapses in maintenance fees.

2. Are the core claims still relevant for current innovation?
Yes; the patent influenced ongoing development, especially in [relevant industry], but specific claims may be limited by prior art or legal challenges.

3. What are the risks of infringing this patent?
Infringement risks are minimal due to patent expiration but historically, enforcement was limited; confirm legal status in specific jurisdictions.

4. How does this patent compare to newer equivalents?
Older in scope and specificity, newer patents tend to incorporate additional features, carriers, or processes to improve upon or bypass the original claims.

5. Could this patent serve as a patentability reference?
Yes; it remains a prior art reference for patent examiners and applicants in related fields assessing novelty.


References

[1] U.S. Patent and Trademark Office. (2023). Patent database. https://patents.google.com/patent/US4795741

More… ↓

⤷  Start Trial

Details for Patent 4,795,741

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Omrix Biopharmaceuticals Ltd EVITHROM thrombin, topical (human) Solution 125247 August 27, 2007 ⤷  Start Trial 2007-05-06
Omrix Biopharmaceuticals Ltd EVITHROM thrombin, topical (human) For Injection 125247 September 17, 2009 ⤷  Start Trial 2007-05-06
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.